precipio is a cancer diagnostics reference laboratory, delivering the latest in advanced diagnostics and personalized medicine. our goal is to assist oncologists in providing the best care for their patients. at the intersection of academia, cancer research, and diagnostics, we connect physicians with world-renown pathologists at the yale school of medicine. at precipio, our customers and their patients benefit from the most accurate, expert diagnosis. we provide our customers exclusive access to some of the most innovative tests in the field of molecular diagnostics, developed through cutting edge research, and the ongoing pursuit and refinement of the science of personalized medicine.
Company profile
Ticker
PRPO
Exchange
Website
CEO
Paul Kinnon
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
TRANSGENOMIC INC
SEC CIK
Corporate docs
Subsidiaries
Precipio Diagnostics, LLC • Precipio SPV, Inc. • CB4Cancer, LLC ...
IRS number
911789357
PRPO stock data
Latest filings (excl ownership)
424B5
Prospectus supplement for primary offering
8 Apr 24
S-8
Registration of securities for employees
29 Mar 24
10-K
2023 FY
Annual report
29 Mar 24
8-K
Precipio Announces Year end 2023 Shareholder Update Call
26 Mar 24
424B5
Prospectus supplement for primary offering
19 Jan 24
8-K
Precipio Announces Christina Valauri joins the Board of Directors
2 Jan 24
8-K
Regulation FD Disclosure
14 Dec 23
8-K
Precipio Announces Q3-2023 Shareholder Update Call
16 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Other Events
6 Oct 23
Transcripts
PRPO
Earnings call transcript
2023 Q3
20 Nov 23
PRPO
Earnings call transcript
2023 Q2
17 Aug 23
PRPO
Earnings call transcript
2023 Q1
17 May 23
PRPO
Earnings call transcript
2022 Q4
3 Apr 23
PRPO
Earnings call transcript
2022 Q3
14 Nov 22
PRPO
Earnings call transcript
2022 Q2
16 Aug 22
PRPO
Earnings call transcript
2021 Q4
4 Apr 22
PRPO
Earnings call transcript
2021 Q3
16 Nov 21
PRPO
Earnings call transcript
2021 Q2
27 Aug 21
PRPO
Earnings call transcript
2021 Q1
21 May 21
Latest ownership filings
4
KATHLEEN LAPORTE
17 Apr 24
4
RICHARD A SANDBERG
17 Apr 24
4
Jeffrey Cossman
17 Apr 24
4
David Seth Cohen
17 Apr 24
4
RONALD ASBURY ANDREWS
17 Apr 24
4
Christina Rizopoulos Valauri
17 Apr 24
4
Christina Rizopoulos Valauri
4 Jan 24
3
Christina Rizopoulos Valauri
4 Jan 24
4
Douglas Carl Fisher
31 Oct 23
4
RICHARD A SANDBERG
26 Oct 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.56 mm | 1.56 mm | 1.56 mm | 1.56 mm | 1.56 mm | 1.56 mm |
Cash burn (monthly) | 337.00 k | 298.50 k | 485.00 k | 758.67 k | 298.67 k | 431.08 k |
Cash used (since last report) | 2.33 mm | 2.06 mm | 3.35 mm | 5.24 mm | 2.06 mm | 2.98 mm |
Cash remaining | -767.14 k | -501.05 k | -1.79 mm | -3.68 mm | -502.20 k | -1.42 mm |
Runway (months of cash) | -2.3 | -1.7 | -3.7 | -4.9 | -1.7 | -3.3 |
Institutional ownership, Q3 2023
10.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 12 |
Opened positions | 4 |
Closed positions | 10 |
Increased positions | 0 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 869.08 mm |
Total shares | 154.91 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Walleye Capital | 52.08 k | $292.16 mm |
Vanguard | 45.05 k | $252.72 mm |
BLK Blackrock | 28.97 k | $162.53 mm |
Geode Capital Management | 14.35 k | $80.53 mm |
Susquehanna International | 11.16 k | $62.59 mm |
Tower Research Capital | 2.36 k | $13.25 mm |
WFC Wells Fargo & Co. | 560.00 | $3.14 mm |
UBS UBS Group AG - Registered Shares | 340.00 | $1.91 mm |
Advisor | 40.00 | $224.00 k |
FMR | 6.00 | $34.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Christina Rizopoulos Valauri | Common Stock | Grant | Acquire A | No | No | 6.74 | 1,446 | 9.75 k | 1,446 |
15 Apr 24 | Cohen David Seth | Common Stock | Grant | Acquire A | No | No | 6.67 | 3,575 | 23.85 k | 42,746 |
15 Apr 24 | Andrews Ronald Asbury | Common Stock | Grant | Acquire A | No | No | 6.66 | 3,153 | 21.00 k | 7,461 |
15 Apr 24 | Cossman Jeffrey | Common Stock | Grant | Acquire A | No | No | 6.7 | 8,143 | 54.56 k | 8,461 |
15 Apr 24 | Sandberg Richard A | Common Stock | Grant | Acquire A | No | No | 6.66 | 5,913 | 39.38 k | 16,033 |